Skip to main content

Abstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress)

Conferences
Ulaner, GA; Esfahani, S; O'Shaughnessy, J; Iagaru, A; Juric, D; Prasad, V; Shields, AF; Opneja, A; Braat, AJAT; Fendler, WP; Liu, J; Cioci, R ...
Published in: Cancer Research
April 17, 2026

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Research

DOI

EISSN

1538-7445

ISSN

0008-5472

Publication Date

April 17, 2026

Volume

86

Issue

8_Supplement

Start / End Page

CT073 / CT073

Publisher

American Association for Cancer Research (AACR)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ulaner, G. A., Esfahani, S., O’Shaughnessy, J., Iagaru, A., Juric, D., Prasad, V., … Almaguel, F. (2026). Abstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress). In Cancer Research (Vol. 86, pp. CT073–CT073). American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.am2026-ct073
Ulaner, Gary A., Shadi Esfahani, Joyce O’Shaughnessy, Andrei Iagaru, Dejan Juric, Vikas Prasad, Anthony F. Shields, et al. “Abstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress).” In Cancer Research, 86:CT073–CT073. American Association for Cancer Research (AACR), 2026. https://doi.org/10.1158/1538-7445.am2026-ct073.
Ulaner GA, Esfahani S, O’Shaughnessy J, Iagaru A, Juric D, Prasad V, et al. Abstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress). In: Cancer Research. American Association for Cancer Research (AACR); 2026. p. CT073–CT073.
Ulaner, Gary A., et al. “Abstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress).” Cancer Research, vol. 86, no. 8_Supplement, American Association for Cancer Research (AACR), 2026, pp. CT073–CT073. Crossref, doi:10.1158/1538-7445.am2026-ct073.
Ulaner GA, Esfahani S, O’Shaughnessy J, Iagaru A, Juric D, Prasad V, Shields AF, Opneja A, Braat AJAT, Fendler WP, Liu J, Cioci R, Shoucair I, Almaguel F. Abstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress). Cancer Research. American Association for Cancer Research (AACR); 2026. p. CT073–CT073.

Published In

Cancer Research

DOI

EISSN

1538-7445

ISSN

0008-5472

Publication Date

April 17, 2026

Volume

86

Issue

8_Supplement

Start / End Page

CT073 / CT073

Publisher

American Association for Cancer Research (AACR)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology